MiCardia’s Dynaplasty Technology Gets 510(k)
MiCardia Corporation, developer of treatments for late-stage congestive heart failure and mitral heart valve disease, announced 510(k) clearance this week for its Dynaplasty Annuloplasty Band […]
Articles by Doug Cress
What’s Next for NexMed?
After NexMed announced it would shelve its previously filed NDA for a toe nail fungus (TNF) treatment following disappointing Phase III clinical results, shares of the […]
Investors Flee Spectranetics as Fed Investigates
In an announcement that sent investors clamoring for cover, the U.S. District Court of Colorado served Spectranetics with a search warrant. It seems that both […]
Could Sumatriptan Oral Spray Relieve Investor’s Headaches?
NovaDel has developed an oral spray technology with applications in a broad range of therapeutic areas and product categories. Spray formulations contain the drug in […]
[Device Profile] Long Term Data Supports Use of Powerlink
An abdominal aortic aneurysm (AAA) is a weakening of the wall of the aorta (the largest artery in the body), resulting in a balloon-like enlargement. […]
Thermage Rejects Unsolicited Buyout
Thermage, a company that has readily maintained its position in an otherwise weak aesthetics market, rejected the previously announced offer to acquire its outstanding shares […]
HemCon Expands Reach with New Licensing Agreement
HemCon has signed an agreement with Institute of Technology Sligo, Ireland, to license a controlled release hydrogen peroxide technology. The technology has broad spectrum antibacterial […]
[Video Profile] Interview with Thomas Harold, Founder & CEO of ScyFIX
Age-Related Macular Degeneration (AMD) is the leading cause of blindness in persons over 50 throughout the western hemisphere. But despite the prevalence and severity of […]
FDA Clears Stereotaxis Guidewire for Peripheral Chronic Total Occlusions
Conventional catheters are designed to be operated mechanically from their proximal or back end. They are necessarily stiff to allow for steering through a series […]
NexMed Gets Nailed, Stock Price Derails
On Tuesday, NexMed announced that it would shelve its previously filed NDA for an onychomycosis treatment (NM100060) following disappointing Phase III clinical results. Onychomycosis, or […]